6533b873fe1ef96bd12d4c5f
RESEARCH PRODUCT
PCA3 as a second-line biomarker in a prospective controlled randomized opportunistic prostate cancer screening programme
Antonio Fernandez-serraÁLvaro Gómez-ferrerM. VanaclochaJosé Rubio-brionesA. ColladoD. SalaF. MartínezA. MolinaR. DumontM. Ramírez-backhausJosé Antonio López-guerreroJ. Domínguez-escrigL. RubioJuan Casanovasubject
AdultMalePCA3medicine.medical_specialty030232 urology & nephrologyUrologyurologic and male genital diseaseslaw.inventionOpportunistic screening03 medical and health sciencesProstate cancerPSA0302 clinical medicineSecond lineRandomized controlled trialAntigens NeoplasmlawBiopsyBiomarkers TumormedicineHumansProspective StudiesEarly Detection of CancerAgedGynecologyProstate cancermedicine.diagnostic_testbusiness.industryProstatic NeoplasmsGeneral MedicineRectal examinationMiddle Agedmedicine.diseaseProstate cancer screening030220 oncology & carcinogenesisBiomarker (medicine)PCA3businessdescription
Objectives: PCA3 performance as a single second line biomarker is compared to the European Randomised Study of Screening for Prostate Cancer risk calculator model 3 (ERSPC RC-3) in an opportunistic screening in prostate cancer (PCa). Material and methods: 5,199 men, aged 40-75y, underwent prostate-specific antigen (PSA) screening and digital rectal examination (DRE). Men with a normal DRE and PSA >= 3 ng/ml had a PCA3 test done. All men with PCA3 >= 35 underwent an initial biopsy (IBx) 12 cores. Men with PCA3 = 3 ng/ml and DRE is normal, IBx could be avoided in 12.5% less than if ERSPC RC-3 is used and would reduce the false negative cases by 36.2%. At a FU of 21.7 months, this dual protocol would miss 9.1% of clinically significant PCa, so strict FU is mandatory with established biopsy criteria based on PSA and DRE in cases with PCA3 < 35. (C) 2016 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 |